Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors.
Burris HA 3rd, Jones SF, Williams DD, Kathman SJ, Hodge JP, Pandite L, Ho PT, Boerner SA, Lorusso P. Burris HA 3rd, et al. Among authors: pandite l. Invest New Drugs. 2011 Jun;29(3):467-72. doi: 10.1007/s10637-009-9374-x. Epub 2010 Jan 13. Invest New Drugs. 2011. PMID: 20069338 Clinical Trial.
A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies.
Burris HA 3rd, Taylor CW, Jones SF, Koch KM, Versola MJ, Arya N, Fleming RA, Smith DA, Pandite L, Spector N, Wilding G. Burris HA 3rd, et al. Among authors: pandite l. Clin Cancer Res. 2009 Nov 1;15(21):6702-8. doi: 10.1158/1078-0432.CCR-09-0369. Epub 2009 Oct 13. Clin Cancer Res. 2009. PMID: 19825948 Free PMC article. Clinical Trial.
Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer.
Storniolo AM, Pegram MD, Overmoyer B, Silverman P, Peacock NW, Jones SF, Loftiss J, Arya N, Koch KM, Paul E, Pandite L, Fleming RA, Lebowitz PF, Ho PT, Burris HA 3rd. Storniolo AM, et al. Among authors: pandite l. J Clin Oncol. 2008 Jul 10;26(20):3317-23. doi: 10.1200/JCO.2007.13.5202. Epub 2008 May 19. J Clin Oncol. 2008. PMID: 18490651 Clinical Trial.
Phase I trial of pazopanib in patients with advanced cancer.
Hurwitz HI, Dowlati A, Saini S, Savage S, Suttle AB, Gibson DM, Hodge JP, Merkle EM, Pandite L. Hurwitz HI, et al. Among authors: pandite l. Clin Cancer Res. 2009 Jun 15;15(12):4220-7. doi: 10.1158/1078-0432.CCR-08-2740. Epub 2009 Jun 9. Clin Cancer Res. 2009. PMID: 19509175 Clinical Trial.
A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors.
Helft PR, Schilsky RL, Hoke FJ, Williams D, Kindler HL, Sprague E, DeWitte M, Martino HK, Erickson J, Pandite L, Russo M, Lambert JM, Howard M, Ratain MJ. Helft PR, et al. Among authors: pandite l. Clin Cancer Res. 2004 Jul 1;10(13):4363-8. doi: 10.1158/1078-0432.CCR-04-0088. Clin Cancer Res. 2004. PMID: 15240523 Clinical Trial.
Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer.
Robertson MJ, Mier JW, Logan T, Atkins M, Koon H, Koch KM, Kathman S, Pandite LN, Oei C, Kirby LC, Jewell RC, Bell WN, Thurmond LM, Weisenbach J, Roberts S, Dar MM. Robertson MJ, et al. Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4265-73. doi: 10.1158/1078-0432.CCR-06-0121. Clin Cancer Res. 2006. PMID: 16857801 Clinical Trial.
Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors.
Siegel-Lakhai WS, Beijnen JH, Vervenne WL, Boot H, Keessen M, Versola M, Koch KM, Smith DA, Pandite L, Richel DJ, Schellens JH. Siegel-Lakhai WS, et al. Among authors: pandite l. Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4495-502. doi: 10.1158/1078-0432.CCR-07-0004. Clin Cancer Res. 2007. PMID: 17671135 Clinical Trial.
45 results